DexCom (DXCM) Given a $67.00 Price Target at Oppenheimer

DexCom (NASDAQ:DXCM) received a $67.00 price objective from analysts at Oppenheimer in a note issued to investors on Monday. The firm presently has a “buy” rating on the medical device company’s stock. Oppenheimer’s target price points to a potential upside of 22.51% from the company’s previous close.

Several other equities research analysts also recently weighed in on the stock. Zacks Investment Research downgraded shares of DexCom from a “hold” rating to a “sell” rating in a research report on Tuesday, October 24th. Morgan Stanley reduced their price target on shares of DexCom from $72.00 to $52.00 and set a “neutral” rating for the company in a research report on Friday, November 3rd. TheStreet downgraded shares of DexCom from a “c-” rating to a “d+” rating in a research report on Wednesday, October 25th. BidaskClub raised shares of DexCom from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 12th. Finally, Jefferies Group raised their price target on shares of DexCom from $58.00 to $70.00 and gave the company a “buy” rating in a research report on Friday, December 22nd. Three analysts have rated the stock with a sell rating, six have issued a hold rating and fourteen have given a buy rating to the company. The company has an average rating of “Hold” and an average price target of $67.44.

Shares of DexCom (NASDAQ:DXCM) traded up $0.34 on Monday, hitting $54.69. 694,744 shares of the company traded hands, compared to its average volume of 1,413,491. The company has a market capitalization of $4,723.19, a P/E ratio of -95.95 and a beta of 0.21. The company has a quick ratio of 5.50, a current ratio of 5.86 and a debt-to-equity ratio of 0.84. DexCom has a 12 month low of $42.62 and a 12 month high of $86.32.

In other news, CEO Kevin R. Sayer sold 12,000 shares of DexCom stock in a transaction on Monday, November 20th. The shares were sold at an average price of $55.00, for a total transaction of $660,000.00. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Richard Doubleday sold 1,635 shares of DexCom stock in a transaction on Friday, November 24th. The stock was sold at an average price of $55.53, for a total transaction of $90,791.55. Following the transaction, the executive vice president now owns 65,049 shares in the company, valued at approximately $3,612,170.97. The disclosure for this sale can be found here. Insiders have sold a total of 48,140 shares of company stock worth $2,743,281 in the last quarter. Corporate insiders own 1.70% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. State Street Corp lifted its stake in shares of DexCom by 2.5% during the 2nd quarter. State Street Corp now owns 1,549,843 shares of the medical device company’s stock valued at $113,374,000 after buying an additional 37,581 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its stake in shares of DexCom by 3.2% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 265,019 shares of the medical device company’s stock valued at $12,967,000 after buying an additional 8,171 shares in the last quarter. Peregrine Capital Management LLC lifted its stake in shares of DexCom by 24.5% during the 3rd quarter. Peregrine Capital Management LLC now owns 395,455 shares of the medical device company’s stock valued at $19,348,000 after buying an additional 77,868 shares in the last quarter. Tirschwell & Loewy Inc. lifted its stake in shares of DexCom by 1.1% during the 3rd quarter. Tirschwell & Loewy Inc. now owns 270,595 shares of the medical device company’s stock valued at $13,239,000 after buying an additional 2,900 shares in the last quarter. Finally, Swiss National Bank lifted its stake in shares of DexCom by 3.4% during the 3rd quarter. Swiss National Bank now owns 318,400 shares of the medical device company’s stock valued at $15,578,000 after buying an additional 10,500 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2018/02/12/dexcom-dxcm-given-a-67-00-price-target-at-oppenheimer.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply